The implantable neurostimulation devices market size has grown rapidly in recent years. It will grow from $5.62 billion in 2025 to $6.27 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising prevalence of neurological disorders, expansion of pain management treatments, adoption of implantable stimulation technologies, increasing clinical acceptance of neuromodulation, availability of implantable electronic systems.
The implantable neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to $10.02 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing demand for non-pharmacological therapies, rising focus on precision neuromodulation, expansion of outpatient neurological treatments, growing investment in brain-machine interface research, increasing innovation in stimulation algorithms. Major trends in the forecast period include increasing deployment of advanced neurostimulation therapies, rising adoption of rechargeable stimulation devices, growing use of personalized neuromodulation treatments, expansion of multi-indication neurostimulation systems, enhanced focus on long-term therapy effectiveness.
The increasing prevalence of neurological disorders is expected to drive the growth of the implantable neurostimulation devices market in the coming years. Neurological disorders are conditions that affect the structure or function of the nervous system, resulting in symptoms such as paralysis, seizures, and cognitive impairments. Greater exposure to risk factors such as high blood pressure, developmental abnormalities, trauma, or injury contributes to higher detection rates of these disorders. Implantable neurostimulation devices are used to modulate nerve activity and alleviate symptoms when conventional treatments are ineffective or insufficient. For example, according to the Alzheimer’s Association, a US-based non-profit organization, an estimated 6.9 million Americans aged 65 and older were living with Alzheimer’s disease in 2024, with 73% being 75 years or older. This number is projected to reach 12.7 million by 2050. Thus, the rising prevalence of neurological disorders is expected to fuel the demand for implantable neurostimulation devices.
Companies in the implantable neurostimulation devices market are focusing on developing advanced systems, such as rechargeable brain-sensing neurostimulators, to provide more personalized and adaptive therapy for patients with movement and neurological disorders. These devices are implanted to record real-time brain signals while delivering targeted stimulation, allowing clinicians to fine-tune therapy based on individual neural activity and long-term treatment requirements. For instance, in January 2024, Medtronic, a US-based medical device company, received U.S. Food and Drug Administration (FDA) approval for its Percept RC neurostimulator, a rechargeable deep brain stimulation (DBS) system featuring exclusive BrainSense technology. The device captures and tracks brain signals to optimize personalized therapy. It offers a service life of at least 15 years, flexible directional stimulation programming, and rapid recharging capabilities, providing patients with a durable and customizable option for managing movement disorders.
In September 2023, Amber Therapeutics, a UK-based provider of neuromodulation therapies, acquired Bioinduction for an undisclosed amount. This acquisition strengthens Amber’s strategic capabilities by incorporating Bioinduction’s implantable-device hardware, engineering expertise, and manufacturing know-how to support next-generation neuromodulation solutions. It also accelerates the development and commercialization of Amber-UI by integrating proven implantable neurostimulation technology into Amber’s platform. Bioinduction is a UK-based manufacturer of implantable neurostimulation devices.
Major companies operating in the implantable neurostimulation devices market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, St. Jude Medical LLC, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., Bioness Inc., Saluda Medical Pty Ltd., SceneRay Co. Ltd., NeuroMetrix Inc., Synapse Biomedical Inc., NeuroSigma Inc., Nuvectra Corporation, MicroTransponder Inc., Curonix LLC, Inspire Medical Systems Inc., SetPoint Medical Corporation, ElectroCore Inc.
North America was the largest region in the implantable neurostimulation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neurostimulation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable neurostimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the implantable neurostimulation devices market by increasing costs of imported microelectronics, electrodes, batteries, sensors, and software-enabled control units. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported advanced components, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are increasing therapy system prices and slowing adoption in cost-sensitive healthcare systems. However, they are also driving local manufacturing, regional R&D investment, and development of cost-efficient neurostimulation platforms.
The implantable neurostimulation devices market research report is one of a series of new reports that provides implantable neurostimulation devices market statistics, including implantable neurostimulation devices industry global market size, regional shares, competitors with a implantable neurostimulation devices market share, detailed implantable neurostimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable neurostimulation devices industry. This implantable neurostimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Implantable neurostimulation devices are medical devices designed to deliver electrical stimulation to specific areas of the nervous system to treat various neurological and psychological conditions. These devices are surgically implanted into the body to modulate nerve activity, offering a sophisticated approach for managing conditions that may not respond adequately to medication alone, thereby enhancing patients' quality of life.
The primary types of implantable neurostimulation devices include spinal cord stimulation (SCS), gastric electric stimulation (GES), deep brain stimulation (DBS), sacral nerve stimulation (SNS), vagus nerve stimulation (VNS), and others. Spinal cord stimulation (SCS) therapy uses mild electrical currents to block pain signals from reaching the brain, providing effective management for chronic pain conditions. These devices are applied in treating pain management, Parkinson's disease, urinary and fecal incontinence, epilepsy, gastroparesis, and other conditions. They are used by various end-users, including hospitals, clinics, and ambulatory surgical centers.
The implantable neurostimulation devices market consists of sales of responsive neurostimulation systems, peripheral nerve stimulation systems, cerebral spinal fluid shunt systems and electroceutical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The implantable neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to $10.02 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing demand for non-pharmacological therapies, rising focus on precision neuromodulation, expansion of outpatient neurological treatments, growing investment in brain-machine interface research, increasing innovation in stimulation algorithms. Major trends in the forecast period include increasing deployment of advanced neurostimulation therapies, rising adoption of rechargeable stimulation devices, growing use of personalized neuromodulation treatments, expansion of multi-indication neurostimulation systems, enhanced focus on long-term therapy effectiveness.
The increasing prevalence of neurological disorders is expected to drive the growth of the implantable neurostimulation devices market in the coming years. Neurological disorders are conditions that affect the structure or function of the nervous system, resulting in symptoms such as paralysis, seizures, and cognitive impairments. Greater exposure to risk factors such as high blood pressure, developmental abnormalities, trauma, or injury contributes to higher detection rates of these disorders. Implantable neurostimulation devices are used to modulate nerve activity and alleviate symptoms when conventional treatments are ineffective or insufficient. For example, according to the Alzheimer’s Association, a US-based non-profit organization, an estimated 6.9 million Americans aged 65 and older were living with Alzheimer’s disease in 2024, with 73% being 75 years or older. This number is projected to reach 12.7 million by 2050. Thus, the rising prevalence of neurological disorders is expected to fuel the demand for implantable neurostimulation devices.
Companies in the implantable neurostimulation devices market are focusing on developing advanced systems, such as rechargeable brain-sensing neurostimulators, to provide more personalized and adaptive therapy for patients with movement and neurological disorders. These devices are implanted to record real-time brain signals while delivering targeted stimulation, allowing clinicians to fine-tune therapy based on individual neural activity and long-term treatment requirements. For instance, in January 2024, Medtronic, a US-based medical device company, received U.S. Food and Drug Administration (FDA) approval for its Percept RC neurostimulator, a rechargeable deep brain stimulation (DBS) system featuring exclusive BrainSense technology. The device captures and tracks brain signals to optimize personalized therapy. It offers a service life of at least 15 years, flexible directional stimulation programming, and rapid recharging capabilities, providing patients with a durable and customizable option for managing movement disorders.
In September 2023, Amber Therapeutics, a UK-based provider of neuromodulation therapies, acquired Bioinduction for an undisclosed amount. This acquisition strengthens Amber’s strategic capabilities by incorporating Bioinduction’s implantable-device hardware, engineering expertise, and manufacturing know-how to support next-generation neuromodulation solutions. It also accelerates the development and commercialization of Amber-UI by integrating proven implantable neurostimulation technology into Amber’s platform. Bioinduction is a UK-based manufacturer of implantable neurostimulation devices.
Major companies operating in the implantable neurostimulation devices market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, St. Jude Medical LLC, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., Bioness Inc., Saluda Medical Pty Ltd., SceneRay Co. Ltd., NeuroMetrix Inc., Synapse Biomedical Inc., NeuroSigma Inc., Nuvectra Corporation, MicroTransponder Inc., Curonix LLC, Inspire Medical Systems Inc., SetPoint Medical Corporation, ElectroCore Inc.
North America was the largest region in the implantable neurostimulation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neurostimulation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable neurostimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the implantable neurostimulation devices market by increasing costs of imported microelectronics, electrodes, batteries, sensors, and software-enabled control units. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported advanced components, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are increasing therapy system prices and slowing adoption in cost-sensitive healthcare systems. However, they are also driving local manufacturing, regional R&D investment, and development of cost-efficient neurostimulation platforms.
The implantable neurostimulation devices market research report is one of a series of new reports that provides implantable neurostimulation devices market statistics, including implantable neurostimulation devices industry global market size, regional shares, competitors with a implantable neurostimulation devices market share, detailed implantable neurostimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable neurostimulation devices industry. This implantable neurostimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Implantable neurostimulation devices are medical devices designed to deliver electrical stimulation to specific areas of the nervous system to treat various neurological and psychological conditions. These devices are surgically implanted into the body to modulate nerve activity, offering a sophisticated approach for managing conditions that may not respond adequately to medication alone, thereby enhancing patients' quality of life.
The primary types of implantable neurostimulation devices include spinal cord stimulation (SCS), gastric electric stimulation (GES), deep brain stimulation (DBS), sacral nerve stimulation (SNS), vagus nerve stimulation (VNS), and others. Spinal cord stimulation (SCS) therapy uses mild electrical currents to block pain signals from reaching the brain, providing effective management for chronic pain conditions. These devices are applied in treating pain management, Parkinson's disease, urinary and fecal incontinence, epilepsy, gastroparesis, and other conditions. They are used by various end-users, including hospitals, clinics, and ambulatory surgical centers.
The implantable neurostimulation devices market consists of sales of responsive neurostimulation systems, peripheral nerve stimulation systems, cerebral spinal fluid shunt systems and electroceutical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Implantable Neurostimulation Devices Market Characteristics
3. Implantable Neurostimulation Devices Market Supply Chain Analysis
4. Global Implantable Neurostimulation Devices Market Trends and Strategies
5. Implantable Neurostimulation Devices Market Analysis of End Use Industries
7. Global Implantable Neurostimulation Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Implantable Neurostimulation Devices Total Addressable Market (TAM) Analysis for the Market
9. Implantable Neurostimulation Devices Market Segmentation
10. Implantable Neurostimulation Devices Market Regional and Country Analysis
11. Asia-Pacific Implantable Neurostimulation Devices Market
12. China Implantable Neurostimulation Devices Market
13. India Implantable Neurostimulation Devices Market
14. Japan Implantable Neurostimulation Devices Market
15. Australia Implantable Neurostimulation Devices Market
16. Indonesia Implantable Neurostimulation Devices Market
17. South Korea Implantable Neurostimulation Devices Market
18. Taiwan Implantable Neurostimulation Devices Market
19. South East Asia Implantable Neurostimulation Devices Market
20. Western Europe Implantable Neurostimulation Devices Market
21. UK Implantable Neurostimulation Devices Market
22. Germany Implantable Neurostimulation Devices Market
23. France Implantable Neurostimulation Devices Market
24. Italy Implantable Neurostimulation Devices Market
25. Spain Implantable Neurostimulation Devices Market
26. Eastern Europe Implantable Neurostimulation Devices Market
27. Russia Implantable Neurostimulation Devices Market
28. North America Implantable Neurostimulation Devices Market
29. USA Implantable Neurostimulation Devices Market
30. Canada Implantable Neurostimulation Devices Market
31. South America Implantable Neurostimulation Devices Market
32. Brazil Implantable Neurostimulation Devices Market
33. Middle East Implantable Neurostimulation Devices Market
34. Africa Implantable Neurostimulation Devices Market
36. Implantable Neurostimulation Devices Market Competitive Landscape and Company Profiles
37. Implantable Neurostimulation Devices Market Other Major and Innovative Companies
40. Implantable Neurostimulation Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Implantable Neurostimulation Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses implantable neurostimulation devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for implantable neurostimulation devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable neurostimulation devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Spinal Cord Stimulation (SCS); Gastric Electric Stimulation (GES); Deep Brain Stimulation (DBS); Sacral Nerve Stimulation (SNS); Vagus Nerve Stimulation (VNS); Other Types2) By Application: Pain Management; Parkinson's Disease; Urinary And Fecal Incontinence; Epilepsy; Gastroparesis; Other Applications
3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Spinal Cord Stimulation (SCS): Rechargeable SCS Devices; Non-Rechargeable SCS Devices2) By Gastric Electric Stimulation (GES): Implantable Gastric Stimulators; Adjustable Gastric Stimulators
3) By Deep Brain Stimulation (DBS): DBS Devices for Movement Disorders; DBS Devices for Psychiatric Disorders
4) By Sacral Nerve Stimulation (SNS): SNS Devices for Urinary Incontinence; SNS Devices for Fecal Incontinence
5) By Vagus Nerve Stimulation (VNS): VNS Devices for Epilepsy; VNS Devices for Depression
6) By Other Types: Peripheral Nerve Stimulation (PNS); Cortical Stimulation Devices; Novel Neurostimulation Technologies
Companies Mentioned: Abbott Laboratories; Medtronic PLC; Boston Scientific Corporation; St. Jude Medical LLC; LivaNova PLC; Nevro Corp.; Axonics Inc.; NeuroPace Inc.; Bioness Inc.; Saluda Medical Pty Ltd.; SceneRay Co. Ltd.; NeuroMetrix Inc.; Synapse Biomedical Inc.; NeuroSigma Inc.; Nuvectra Corporation; MicroTransponder Inc.; Curonix LLC; Inspire Medical Systems Inc.; SetPoint Medical Corporation; ElectroCore Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Implantable Neurostimulation Devices market report include:- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- St. Jude Medical LLC
- LivaNova PLC
- Nevro Corp.
- Axonics Inc.
- NeuroPace Inc.
- Bioness Inc.
- Saluda Medical Pty Ltd.
- SceneRay Co. Ltd.
- NeuroMetrix Inc.
- Synapse Biomedical Inc.
- NeuroSigma Inc.
- Nuvectra Corporation
- MicroTransponder Inc.
- Curonix LLC
- Inspire Medical Systems Inc.
- SetPoint Medical Corporation
- ElectroCore Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.27 Billion |
| Forecasted Market Value ( USD | $ 10.02 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
